|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM347722938 |
| 003 |
DE-627 |
| 005 |
20231226034518.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2022.109156
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1159.xml
|
| 035 |
|
|
|a (DE-627)NLM347722938
|
| 035 |
|
|
|a (NLM)36257529
|
| 035 |
|
|
|a (PII)S1521-6616(22)00237-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Tao, Sha-Sha
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Dickkopf-1 as a promising therapeutic target for autoimmune diseases
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 25.11.2022
|
| 500 |
|
|
|a Date Revised 26.12.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2022 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Dickkopf-1 (DKK-1) is mostly known as a mature inhibitor of classic Wnt signaling pathways, which plays a critically role in regulating bone formation and bone metastasis. In recent years, the roles of DKK-1 played in bone resorption, bone formation, immune homeostasis and inflammation have been investigated. The role of DKK-1 in the pathogenesis and treatment of autoimmune diseases (ADs), including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), etc, has attracted widespread attention. Various studies have found that DKK-1 may be used as a biomarker for the occurrence and development of ADs, and as a potential target for the treatment of ADs. In this review, we have briefly summed up the intricate immunological functions and regulatory mechanisms of DKK-1 in ADs, aiming to further learning more about the role of DKK-1 involved in the pathogenesis of ADs and provide an outlook for the potential future researches
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Autoimmune diseases
|
| 650 |
|
4 |
|a Biomarker
|
| 650 |
|
4 |
|a DKK-1
|
| 650 |
|
4 |
|a Therapeutic target
|
| 650 |
|
7 |
|a Intercellular Signaling Peptides and Proteins
|2 NLM
|
| 700 |
1 |
|
|a Cao, Fan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sam, Napoleon Bellua
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Hong-Miao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Feng, Ya-Ting
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ni, Jing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Peng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Xiao-Mei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pan, Hai-Feng
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 245(2022) vom: 15. Dez., Seite 109156
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:245
|g year:2022
|g day:15
|g month:12
|g pages:109156
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.109156
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 245
|j 2022
|b 15
|c 12
|h 109156
|